Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen OLE in Cardiovascular Disease and Elevated Lp(a)
NCT07517263Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2026
- Primary completion
- Jan 2030
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 40
01
Overview
A Phase 3 trial of pelacarsen in cardiovascular disease (CVD), elevated lipoprotein(a) (Lp(a)), sponsored by Novartis. Started May 2026; status: active, not recruiting.
02
Drugs
pelacarsen
03
Conditions
cardiovascular disease (CVD)elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT07517263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07517263.